SCHEMBL23966690

SCHEMBL23966690

CC(C)(C)c1cc(C2(C)CC2)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 1/20 0.41
EGFR P00533 3/20 0.40
EPHX2 P34913 2/20 0.35
CNR1 P21554 3/20 0.34
CNR2 P34972 3/20 0.34
NPC1 O15118 5/20 0.33
RAB9A P51151 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
BRD4 O60885 1/20 0.33
MAPK14 Q16539 2/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
PKM P14618 1/20 0.31
TSHR P16473 1/20 0.31
HTT P42858 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23966699 0.93 MEN1 (0.42) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL23966743 0.85 MEN1 (0.42) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL23966711 0.77 MEN1 (0.38) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL23966700 0.75 MEN1 (0.37) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL25792548 0.74 MEN1 (0.36) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL23966641 0.74 MEN1 (0.36) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL16590521 0.74 SLC6A2 (0.38) KMT2AHPGDEGFREPHX2CNR2
SCHEMBL23966701 0.73 HPGD (0.36) MEN1KMT2AHPGDEGFREPHX2
SCHEMBL1256152 0.72 KDM4E (0.35) CNR2ALDH1A1
SCHEMBL23966638 0.71 MEN1 (0.33) MEN1KMT2AHPGDEGFRCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 MEN1 1766/4885KMT2A 2554/4885HPGD 2524/4885
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 MEN1 1800/4885KMT2A 2881/4885HPGD 2484/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 MEN1 1766/4885KMT2A 2554/4885HPGD 2524/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 MEN1 3098/4885KMT2A 4530/4885HPGD 1303/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 MEN1 1766/4885KMT2A 2554/4885HPGD 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.